skip to main content

brainstorm askiatroX medicines

simulations beta

loading page…

learn & practise

exams international doctors free questions Socratic Tutor rounds stat clinical connections academy journal tool guides

clinical reference

askiatroX knowledge centre medicines UK / NICE guidance international guidance calculators q&a library

trust & support

how it works methodology account & support frequently asked questions about us clinical safety consultancy

legal

mobile app · scan to download

Medicines ranibizumabQuestion & answer

ranibizumab · Medicine question

Which receptors does ranibizumab prevent VEGF-A from binding to?

iatroX medicinesPublished 8 November 2026

The answer

Answer

Ranibizumab prevents VEGF-A from binding to its receptors VEGFR-1 and VEGFR-2.

Sources for this answer

Lucentis 10 mg/ml solution for injectionNovartis Pharmaceuticals UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 33Document updated 31 July 2023

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

The full medicine guide

More questions about ranibizumab

Can ranibizumab (Lucentis) be administered concurrently with other anti-VEGF medicines?Are data available on the effects of ranibizumab on fertility?Can ranibizumab (Lucentis) cause increased pressure inside the eye in adults?Did thiazolidinediones affect the visual or retinal thickness outcomes of ranibizumab (Lucentis) in diabetic macular oedema studies?Has the safety and efficacy of ranibizumab (Lucentis) been established in children under 18 for conditions other than retinopathy of prematurity?

ranibizumab

Read the wider context, including uses, precautions and the sources behind this medicine guide.

Read the ranibizumab guide

More clinical questions?

Explore the tools and reference material available on iatroX.

Explore askiatroX

What are the most frequently reported non-eye side effects of ranibizumab (Lucentis)?